Cordyceps militaris

Metadata

Regulatory Status

United States

• Dietary supplement: Yes. Widely sold under DSHEA as a dietary supplement. C. militaris fruiting body products are the dominant commercial form in the US market.
• FDA GRAS status: No specific GRAS determination for C. militaris extracts.
• NDI status: Several C. militaris preparations have been the subject of New Dietary Ingredient (NDI) notifications to the FDA.

European Union

• Novel food: Cordyceps militaris mycelium biomass and fruiting body preparations have received novel food authorization under Regulation (EU) 2015/2283 in certain member states. Concentrated cordycepin-enriched extracts may require separate authorization.
• EMA/HMPC: No assessment report or community herbal monograph. Cordyceps species fall outside the European phytotherapy tradition.
• Commission E / ESCOP: No monographs exist.

China

• Chinese Pharmacopoeia: C. militaris is not separately listed in the Chinese Pharmacopoeia (which lists only Ophiocordyceps sinensis as the official Cordyceps drug). However, C. militaris is recognized by the Chinese Ministry of Health as a “new food resource” (Xin Shi Pin Yuan Liao) since 2009, approved for use in food and health products.
• Functional food status: Approved as a raw material for health food products by China’s State Administration for Market Regulation (SAMR).

Japan

• Japanese Pharmacopoeia: Not listed.
• Health food: Available as a dietary supplement and functional food. Japanese researchers have contributed significantly to C. militaris cultivation technology and bioactive characterization.

Korea

• Korean traditional medicine (Hanbang): Recognized and used within the Korean traditional medicine framework.
• Commercial cultivation: Korea is one of the leading producers of cultivated C. militaris, with industrial-scale solid-state fermentation facilities. The Korean Food and Drug Safety Ministry (MFDS) recognizes C. militaris as a food ingredient.

Conditions & Indications

Primary: Exercise Performance and Energy (Moderate Evidence)

• VO2 max and aerobic capacity: Hirsch et al. (2017) demonstrated that 3 weeks of C. militaris-containing mushroom blend supplementation (4 g/day) improved VO2 max by approximately 11% in healthy young adults (18—35 yr) compared to placebo in a double-blind RCT. No significant effect was observed after only 1 week, suggesting a loading period is required for ergogenic benefit.
• Time-to-exhaustion: Supplementation with C. militaris extracts has shown improvements in time-to-exhaustion in both young and elderly populations. The proposed mechanism involves enhanced mitochondrial ATP production via AMPK/PGC-1alpha pathway activation and improved cellular oxygen utilization through adenosine receptor-mediated vasodilation.
• Anti-fatigue effects: Small controlled trials demonstrate reduced subjective fatigue scores and improved exercise tolerance, particularly in elderly or deconditioned individuals. Effects may be less pronounced in well-trained athletes, consistent with a ceiling effect where baseline aerobic capacity is already optimized.

Secondary: Immune Modulation (Preliminary Evidence)

• Innate immune activation: C. militaris beta-glucan polysaccharides stimulate macrophage phagocytosis, NK cell cytotoxicity, and dendritic cell maturation through dectin-1 and TLR-2 receptor signaling. Multiple in vitro and animal studies confirm dose-dependent immune activation.
• Cytokine modulation: Ahn et al. (2000) and subsequent studies demonstrated that C. militaris water extracts enhance Th1 cytokine production (IL-2, IFN-gamma) while modulating Th2 responses, suggesting immunoregulatory rather than purely immunostimulant activity.
• Adjunctive cancer support: Preclinical evidence supports immune-mediated anti-tumor activity via NK cell and macrophage activation. Lee et al. (2006) demonstrated that C. militaris polysaccharide fractions enhanced splenocyte proliferation and NK cell activity in tumor-bearing mice. Human clinical data for oncology applications remains absent.

Secondary: Anti-Inflammatory and Metabolic Effects (Preliminary Evidence)

• Anti-inflammatory activity: Cordycepin inhibits NF-kB signaling, reducing production of TNF-alpha, IL-1beta, and IL-6 in activated immune cells. This has been demonstrated in multiple in vitro and animal models of inflammation.
• Blood glucose regulation: Animal studies suggest hypoglycemic effects through enhanced insulin sensitivity and modulation of hepatic glucose output. Dong et al. (2014) demonstrated that C. militaris polysaccharides reduced fasting blood glucose and improved glucose tolerance in diabetic mice. Clinical evidence in humans is insufficient for recommendation.

Emerging: Neuroprotective and Anti-Aging (Preclinical)

• Neuroprotection: Cordycepin and C. militaris extracts have demonstrated neuroprotective effects in animal models of neurodegeneration, potentially mediated through adenosine receptor signaling, anti-neuroinflammatory activity, and enhancement of nerve growth factor (NGF) secretion.
• Anti-aging: Ergothioneine and other antioxidant compounds in C. militaris have shown anti-senescence effects in cellular models. The carotenoid pigments unique to C. militaris (responsible for its orange coloration) contribute additional antioxidant capacity not present in O. sinensis.
• Testosterone and reproductive function: Animal studies suggest C. militaris supplementation may increase testosterone production and sperm quality, but human clinical data is limited to small, poorly controlled trials.

Mechanism of Action

Cordycepin (3’-Deoxyadenosine) — Primary Bioactive

Cordycepin is the signature and most pharmacologically characterized bioactive of C. militaris. It is an adenosine analog lacking a hydroxyl group at the 3’ position of the ribose sugar. This structural feature enables several distinct mechanisms:

1. Adenosine receptor modulation: Cordycepin interacts with all four adenosine receptor subtypes (A1, A2A, A2B, A3). A2A receptor agonism mediates vasodilation and anti-inflammatory effects; A1 agonism contributes to cardioprotective and sedative activity; A3 receptor modulation is associated with anti-proliferative effects.
2. RNA chain termination: Due to the missing 3’-OH group, cordycepin incorporation into nascent RNA causes premature chain termination and inhibits mRNA polyadenylation, the principal mechanism underlying its anti-cancer activity in preclinical models.
3. AMPK activation: Cordycepin activates AMP-activated protein kinase (AMPK), a master metabolic sensor. AMPK activation enhances mitochondrial biogenesis (via PGC-1alpha), increases fatty acid oxidation, improves insulin sensitivity, and inhibits mTOR-dependent protein synthesis in cancer cells.
4. NF-kB inhibition: Cordycepin suppresses NF-kB nuclear translocation through inhibition of IKK phosphorylation, reducing expression of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6), cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS).

Cordycepin concentration advantage: Cultivated C. militaris fruiting bodies typically produce 3—8 mg/g cordycepin, compared to less than 1 mg/g in wild O. sinensis specimens. This difference is the primary pharmacological argument for preferring C. militaris when cordycepin-mediated effects are the therapeutic target. Optimization of cultivation substrates and conditions can further enhance cordycepin yield; rice-based substrates supplemented with specific amino acids have been shown to maximize cordycepin production.

Beta-Glucan Polysaccharides

C. militaris produces a characteristic polysaccharide profile dominated by beta-(1,3)-D-glucans with (1,6) branching. These polysaccharides activate innate immune cells through pattern recognition receptors, primarily dectin-1 and TLR-2 on macrophages and dendritic cells. Downstream signaling increases phagocytic activity, NK cell cytotoxicity, and pro-inflammatory cytokine production appropriate for pathogen defense. The polysaccharide profile of C. militaris is broadly similar to but quantitatively distinct from O. sinensis, with some unique heteroglycan fractions identified.

Mitochondrial Bioenergetics Enhancement

Cordycepin and C. militaris extracts upregulate mitochondrial biogenesis through the AMPK/PGC-1alpha/TFAM signaling cascade. This increases mitochondrial density, enhances oxidative phosphorylation capacity, and improves cellular ATP/ADP ratios. Combined with adenosine receptor-mediated vasodilation (improving oxygen delivery to tissues), this mechanism provides the pharmacological basis for the observed exercise performance and anti-fatigue effects.

Carotenoid Pigments (Species-Specific)

The bright orange color of C. militaris fruiting bodies is due to carotenoid pigments, primarily cordyxanthin, which are absent from O. sinensis. These carotenoids contribute antioxidant capacity through singlet oxygen quenching and free radical scavenging. While their clinical significance is not yet established, they represent a bioactive fraction unique to this species.

Pharmacokinetic Considerations

Cordycepin has a short in vivo half-life (approximately 1.6 minutes in rodent models) due to rapid deamination by adenosine deaminase (ADA). Oral bioavailability of cordycepin from whole mushroom preparations appears higher than from isolated cordycepin, possibly due to matrix effects from other constituents. Some evidence suggests that pentostatin (an ADA inhibitor) and other natural ADA inhibitors present in the mushroom extract itself may partially protect cordycepin from degradation. Dual extraction (hot water + ethanol) captures both water-soluble polysaccharides and alcohol-soluble cordycepin, providing the broadest bioactive spectrum.

Clinical Evidence Summary

Clinical evidence specific to C. militaris (as distinct from Cs-4 or wild O. sinensis) is growing but still limited in volume. The species-specific evidence base is smaller than that for the broader “cordyceps” category, but key trials have demonstrated effects consistent with the pharmacological profile.

Exercise Performance

Immune Modulation

Anti-Fatigue

Evidence Limitations

• Most RCTs are small (n = 28—79), single-center, and short-duration (3—12 weeks).
• The Hirsch et al. (2017) trial used a mushroom blend containing C. militaris alongside other ingredients, complicating attribution of effects specifically to C. militaris.
• No large (n > 100), multi-center, independently funded RCTs using standardized C. militaris-only preparations have been published.
• Many studies originate from East Asian research groups with potential funding from supplement manufacturers. Independent replication in Western research settings is limited.
• Dosing and extract standardization vary considerably across trials, making cross-study comparison difficult.
• Long-term safety and efficacy data (beyond 12 weeks) are absent from the clinical literature.
• The distinction between effects of cordycepin vs. polysaccharides vs. whole-extract activity remains incompletely characterized in human subjects.

Safety Profile

General Assessment

Cordyceps militaris cultivated fruiting body preparations appear generally well-tolerated in published clinical trials and in the context of widespread commercial use as a dietary supplement and food ingredient. The species has a long history of consumption in East Asian cuisine (particularly in Korea and China) and has been approved as a food resource by Chinese regulatory authorities since 2009. Systematic long-term safety data from large controlled trials is absent, but the available evidence does not suggest significant acute or subacute toxicity at standard doses.

Contraindications

• Pregnancy and lactation: Contraindicated due to insufficient safety data. No human studies in pregnant or lactating women have been conducted. Some preclinical evidence suggests potential effects on reproductive hormones (testosterone modulation).
• Autoimmune disease: Theoretical concern that immunostimulatory beta-glucans could exacerbate autoimmune conditions. Clinical evidence for this interaction is absent but the immunostimulatory mechanism provides a plausible theoretical basis for caution.
• Pre-surgical: Discontinue at least 2 weeks before surgery due to potential antiplatelet activity of cordycepin and adenosine.

Drug Interactions

• Anticoagulants and antiplatelets (warfarin, heparin, aspirin, clopidogrel): Cordycepin demonstrates antiplatelet activity in vitro and in animal models. Theoretical risk of additive bleeding when combined with anticoagulant therapy. Monitor INR if co-administered with warfarin.
• Immunosuppressants (cyclosporine, tacrolimus, cyclophosphamide): Beta-glucan polysaccharides may counteract immunosuppressive therapy. Avoid concurrent use in transplant patients or those on immunosuppressive regimens without physician guidance.
• Antidiabetic medications: Potential additive hypoglycemic effects based on animal data. Monitor blood glucose if co-administered with insulin or oral hypoglycemics.
• Theophylline: Cordycepin, as an adenosine analog, may interact with theophylline (an adenosine receptor antagonist). Clinical significance uncertain.
• CYP450 substrates: Limited in vitro data suggest potential inhibition of CYP1A2, CYP3A4, and CYP2D6. Clinical significance uncertain; exercise caution with narrow-therapeutic-index drugs metabolized by these enzymes.

Side Effects (at Recommended Doses)

• Common: Generally well-tolerated. Mild gastrointestinal discomfort (nausea, diarrhea, abdominal bloating) reported infrequently.
• Uncommon: Allergic reactions in individuals with mold or fungal sensitivities. Dry mouth.
• Rare: No serious adverse events have been reported in published clinical trials at standard doses.

Quality and Contamination Considerations

• Cultivation advantage: Unlike wild-harvested O. sinensis, cultivated C. militaris is produced under controlled conditions, significantly reducing the risk of heavy metal contamination, microbial contamination, and species adulteration.
• Substrate residues: C. militaris is typically cultivated on rice or grain substrates. The finished product may contain residual substrate material, which should be distinguished from actual fungal biomass. Products standardized to cordycepin or beta-glucan content are preferable.
• Third-party testing: Despite the cultivation advantage, third-party testing for heavy metals, pesticide residues, and microbial contamination remains advisable, particularly for imported products.

Clinical Dosage

Cultivated C. militaris Fruiting Body Powder

• Standard dose: 1—4 g/day of dried fruiting body powder, divided into 1—2 doses
• Exercise performance context: Hirsch et al. (2017) used 4 g/day of a C. militaris-containing blend for 3 weeks to achieve VO2 max improvements
• General supplementation: 1—3 g/day is the most common commercial dosing range

Hot-Water Extract

• Standard dose: 500—1,500 mg/day of hot-water extract, typically standardized to polysaccharide/beta-glucan content (>30%)
• Primary target: Immune modulation via polysaccharide fraction
• Note: Hot-water extraction preferentially captures polysaccharides but may leave behind cordycepin (which is partially ethanol-soluble)

Dual-Extraction (Water + Ethanol)

• Standard dose: 500—1,000 mg/day of dual extract
• Standardization: Preferably standardized to both cordycepin content (>0.5%) and polysaccharide content (>20%)
• Rationale: Captures both water-soluble polysaccharides and alcohol-soluble cordycepin, providing the broadest bioactive profile

Cordycepin-Standardized Extract

• Dose varies by product: Depending on cordycepin concentration, typically 200—600 mg of extract standardized to a specified cordycepin percentage
• Emerging approach: Cordycepin-specific standardization is increasingly available but dosing remains empirical due to limited pharmacokinetic data in humans

Form Selection Guidance

For exercise performance and energy applications (the primary indication), fruiting body powder or dual-extraction products are preferred due to their higher cordycepin content compared to mycelium-based preparations. For immune modulation, hot-water extracts rich in beta-glucans are adequate. Dual-extraction products that capture both water-soluble polysaccharides and alcohol-soluble cordycepin offer the broadest therapeutic spectrum and are recommended when the clinical goal encompasses both energy and immune support.

Sources

• Hirsch KR, Smith-Ryan AE, Roelofs EJ, Trexler ET, Mock MG. Cordyceps militaris improves tolerance to high-intensity exercise after acute and chronic supplementation. J Diet Suppl. 2017;14(1):42-53
• Cunningham KG, Manson W, Spring FS, Hutchinson SA. Cordycepin, a metabolic product isolated from cultures of Cordyceps militaris (Linn.) Link. Nature. 1950;166(4231):949
• Das SK, Masuda M, Sakurai A, Sakakibara M. Medicinal uses of the mushroom Cordyceps militaris: current state and prospects. Fitoterapia. 2010;81(8):961-968
• Tuli HS, Sandhu SS, Sharma AK. Pharmacological and therapeutic potential of Cordyceps with special reference to cordycepin. 3 Biotech. 2014;4(1):1-12
• Ahn YJ, Park SJ, Lee SG, Shin SC, Choi DH. Cordycepin: selective growth inhibitor derived from liquid culture of Cordyceps militaris against Clostridium spp. J Agric Food Chem. 2000;48(7):2744-2748
• Lee H, Kim YJ, Kim HW, Lee DH, Sung MK, Park T. Induction of apoptosis by Cordyceps militaris through activation of caspase-3 in leukemia HL-60 cells. Biol Pharm Bull. 2006;29(4):670-674
• Kang HJ, Baik HW, Kim SJ, et al. Cordyceps militaris enhances cell-mediated immunity in healthy Korean men. J Med Food. 2015;18(10):1164-1172
• Dong Y, Jing T, Meng Q, et al. Studies on the antidiabetic activities of Cordyceps militaris extract in diet-streptozotocin-induced diabetic Sprague-Dawley rats. BioMed Res Int. 2014;2014:160980
• Song J, Wang Y, Teng M, et al. Cordyceps militaris fruit body extract ameliorates membranous glomerulonephritis by attenuating oxidative stress and renal inflammation. Food Chem Toxicol. 2015;76:76-83
• Jung SJ, Jung ES, Choi EK, Sin HS, Ha KC, Chae SW. Immunomodulatory effects of a mycelium extract of Cordyceps (Paecilomyces hepiali; CBG-CS-2): a randomized and double-blind clinical trial. BMC Complement Med Ther. 2019;19(1):77
• Shrestha B, Zhang W, Zhang Y, Liu X. The medicinal fungus Cordyceps militaris: research and development. Mycol Prog. 2012;11(3):599-614
• Yue K, Ye M, Zhou Z, Sun W, Lin X. The genus Cordyceps: a chemical and pharmacological review. J Pharm Pharmacol. 2013;65(4):474-493
• Paterson RRM. Cordyceps — a traditional Chinese medicine and another fungal therapeutic biofactory? Phytochemistry. 2008;69(7):1469-1495
• Ng TB, Wang HX. Pharmacological actions of Cordyceps, a prized folk medicine. J Pharm Pharmacol. 2005;57(12):1509-1519
• Masuda M, Urabe E, Honda H, Sakurai A, Sakakibara M. Enhanced production of cordycepin by surface culture using the medicinal mushroom Cordyceps militaris. Enzyme Microb Technol. 2007;40(5):1199-1205
• Zheng P, Xia Y, Xiao G, et al. Genome sequence of the insect pathogenic fungus Cordyceps militaris, a valued traditional Chinese medicine. Genome Biol. 2011;12(11):R116

Connections

• Parent species entry: The combined Cordyceps monograph covers both C. militaris and O. sinensis together, including Cs-4 mycelium preparations and the broader cordyceps clinical evidence base. This monograph focuses specifically on C. militaris as a distinct species with unique advantages.
• Sustainability context: C. militaris is the sustainable, commercially cultivable alternative to wild-harvested O. sinensis, which is critically overharvested on the Tibetan Plateau and sells for USD $20,000—100,000/kg. Cultivation of C. militaris via solid-state fermentation on grain substrates provides consistent cordycepin levels at a fraction of the cost, with no ecological impact.
• Cordycepin advantage: C. militaris fruiting bodies contain 3—8 mg/g cordycepin vs. <1 mg/g in wild O. sinensis, making it the preferred species when cordycepin-mediated effects (anti-inflammatory, exercise performance, anti-proliferative) are the therapeutic target.
• Immune modulation parallels: The beta-glucan immune stimulation of C. militaris parallels that of Reishi, Turkey Tail, Maitake, and Chaga. All share dectin-1/TLR-2 mediated innate immune activation, but C. militaris is unique among these species in its concurrent adenosine-analog pharmacology via cordycepin.
• Cognitive-neuro crossover: The neuroprotective properties of cordycepin (adenosine receptor modulation, anti-neuroinflammation) provide potential complementarity with Lion’s Mane, which acts through a distinct mechanism (hericenone/erinacine-mediated NGF stimulation). Combination protocols targeting both neuroinflammation and neurotrophic support are an emerging area of interest.
• Form-dependent pharmacology: Unlike the Cs-4 mycelium preparations derived from O. sinensis culture, C. militaris fruiting body products offer a more complete and cordycepin-rich bioactive profile. This mirrors the broader fruiting body vs. mycelium discussion relevant across medicinal mycology.